Cargando…

Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis

We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC). We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Peng, Guo, Run-Qi, Song, Gang, Yang, Kai-Wei, Zhang, Lei, Li, Xue-Song, Zhang, Kai, Zhou, Li-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219310/
https://www.ncbi.nlm.nih.gov/pubmed/30084431
http://dx.doi.org/10.4103/aja.aja_57_18
_version_ 1783368635325087744
author Hong, Peng
Guo, Run-Qi
Song, Gang
Yang, Kai-Wei
Zhang, Lei
Li, Xue-Song
Zhang, Kai
Zhou, Li-Qun
author_facet Hong, Peng
Guo, Run-Qi
Song, Gang
Yang, Kai-Wei
Zhang, Lei
Li, Xue-Song
Zhang, Kai
Zhou, Li-Qun
author_sort Hong, Peng
collection PubMed
description We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC). We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard meta-analysis on survival outcomes. Our meta-analysis included eight eligible studies with 686 patients. The results were as follows: progression-free survival (PFS) was associated with CgA level (hazard ratio [HR] = 2.47, 95% confidence interval [CI]: 1.47–4.14, P = 0.0006); PFS was relative to CgA change (HR = 9.22, 95% CI: 3.03–28.05, P < 0.0001); and overall survival (OS) was relative to CgA level (HR = 1.47, 95% CI: 1.15–1.87, P = 0.002). When we divided the patients into two groups according to therapy status, the result for OS relative to CgA level was an HR of 1.26 (95% CI: 1.09–1.45, P = 0.001) in the first-line hormonal therapy group, and an HR of 2.33 (95% CI: 1.40–3.89, P = 0.001) in the second-line hormonal therapy or chemotherapy group. This meta-analysis indicated that a high CgA level had a negative influence on OS and PFS in CRPC patients. In addition, CRPC patients with a rising CgA had a shorter PFS. Further studies are needed to verify the prognostic value of CgA in CRPC.
format Online
Article
Text
id pubmed-6219310
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-62193102018-11-30 Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis Hong, Peng Guo, Run-Qi Song, Gang Yang, Kai-Wei Zhang, Lei Li, Xue-Song Zhang, Kai Zhou, Li-Qun Asian J Androl Original Article We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC). We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard meta-analysis on survival outcomes. Our meta-analysis included eight eligible studies with 686 patients. The results were as follows: progression-free survival (PFS) was associated with CgA level (hazard ratio [HR] = 2.47, 95% confidence interval [CI]: 1.47–4.14, P = 0.0006); PFS was relative to CgA change (HR = 9.22, 95% CI: 3.03–28.05, P < 0.0001); and overall survival (OS) was relative to CgA level (HR = 1.47, 95% CI: 1.15–1.87, P = 0.002). When we divided the patients into two groups according to therapy status, the result for OS relative to CgA level was an HR of 1.26 (95% CI: 1.09–1.45, P = 0.001) in the first-line hormonal therapy group, and an HR of 2.33 (95% CI: 1.40–3.89, P = 0.001) in the second-line hormonal therapy or chemotherapy group. This meta-analysis indicated that a high CgA level had a negative influence on OS and PFS in CRPC patients. In addition, CRPC patients with a rising CgA had a shorter PFS. Further studies are needed to verify the prognostic value of CgA in CRPC. Medknow Publications & Media Pvt Ltd 2018 2018-07-31 /pmc/articles/PMC6219310/ /pubmed/30084431 http://dx.doi.org/10.4103/aja.aja_57_18 Text en Copyright: © The Author(s)(2018) http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Hong, Peng
Guo, Run-Qi
Song, Gang
Yang, Kai-Wei
Zhang, Lei
Li, Xue-Song
Zhang, Kai
Zhou, Li-Qun
Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title_full Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title_fullStr Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title_full_unstemmed Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title_short Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
title_sort prognostic role of chromogranin a in castration-resistant prostate cancer: a meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219310/
https://www.ncbi.nlm.nih.gov/pubmed/30084431
http://dx.doi.org/10.4103/aja.aja_57_18
work_keys_str_mv AT hongpeng prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT guorunqi prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT songgang prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT yangkaiwei prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT zhanglei prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT lixuesong prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT zhangkai prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis
AT zhouliqun prognosticroleofchromograninaincastrationresistantprostatecancerametaanalysis